The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs.

van Pelt, L Joost;Lukens, Michaël V;Testa, Sophie;Chatelain, Bernard;Mullier, François;et.al.
(2018) Thrombosis Research : vascular obstruction, hemorrhage and hemostasis — Vol. 168, p. 63-66 (2018)

Files

VanPeltLJThrombRes2018.pdf
  • Closed Access
  • Adobe PDF
  • 342.32 KB
Request a copy

Details

Authors
  • van Pelt, L Joost
    Author
  • Lukens, Michaël V
    Author
  • Testa, Sophie
    Author
  • Chatelain, BernardUCLouvain
    Author
  • Mullier, FrançoisUCLouvain
    Author
Show more
Abstract
(en) Direct oral anticoagulants (DOACs) have predictable anticoagulant effects with established efficacy and safety profiles [ 1 ]. In general, drug monitoring is not necessary, but specific drug measurement can be an urgent need in specific clinical situations [ 2 , 3 ]. DOAC specific laboratory tests have been developed for several commercial coagulation platforms. All of the tests developed for the anti-Xa drugs are based on the inhibitory effects of DOACs on activated factor X (FXa) in the assay system. Currently, few laboratories have implemented these tests. They are relatively expensive – the price amounts to approximately 10 EUR if more than 10 tests are requested per week and may be a multiple of that amount if the number of requests is lower – but more importantly, they are difficult to handle in a 24/7 routine laboratory setting due to a complex measurement system with specific calibrators and controls.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

van Pelt, L. J., Lukens, M. V., Testa, S., Chatelain, B., Douxfils, J., & Mullier, F. (2018). The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. Thrombosis Research : vascular obstruction, hemorrhage and hemostasis, 168, 63-66. https://doi.org/10.1016/j.thromres.2018.04.024 (Original work published 2018)